Chemoprevention acceptance and adherence in women with high-risk breast lesions
Menée auprès de 536 patientes présentant une hyperplasie mammaire atypique ou un carcinome lobulaire in situ (âge moyen : 52 ans), cette étude évalue, du point de vue de la proportion des patientes ayant accepté un traitement chimiopréventif et ayant achevé ce traitement, l'efficacité d'une consultation personnalisée destinée d'une part à informer les patientes sur leurs risques de développer un cancer mammaire et, d'autre part, à les conseiller dans leur choix thérapeutique
Patients with atypical hyperplasia and lobular carcinoma in situ (LCIS) (atypical breast lesions) are at high risk of developing breast cancer, and chemoprevention has been shown to confer a substantial reduction in that risk. Despite this, the overall rate of chemoprevention utilization in this group is low. This study evaluates the efficacy of a formal individualized education and counseling session on patient acceptance and adherence to chemoprevention. Patients with atypical breast lesions having an individualized education and counseling session in a single surgical oncology practice were prospectively entered into a database from 2001 to 2016, and with IRB approval, their data were analyzed. Chemoprevention recommendations, acceptance, duration of treatment, and side effects were recorded. A total of 536 patients were included in this study. Mean age at diagnosis was 52 years (range: 19-86 years). Chemoprevention was recommended for 386 (72%) of whom 199 (52%) elected to take medication or participate in a chemoprevention clinical trial. At the time of this writing, 72 patients had completed therapy, 69 were still in treatment, and 58 had stopped chemoprevention prematurely. Approximately 55% of the women who accepted chemoprevention in this study will complete 5 years of therapy. A formal individualized education and counseling session can improve chemoprevention acceptance and achieve a reasonable completion rate, thus reducing cancer incidence in women with atypical breast lesions.